Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 7/20 | 0.62 |
| ▸ | CCND1 | P24385 | 7/20 | 0.62 |
| ▸ | CCND3 | P30281 | 5/20 | 0.62 |
| ▸ | CCND2 | P30279 | 4/20 | 0.62 |
| ▸ | CDK2 | P24941 | 4/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.54 |
| ▸ | CDK9 | P50750 | 2/20 | 0.54 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.54 |
| ▸ | CCNK | O75909 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 3/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14681895 | 0.90 | CDK4 (0.55) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL5868589 | 0.87 | CDK4 (0.59) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL13616064 | 0.84 | CDK4 (0.61) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL7713038 | 0.81 | CCND3 (0.61) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL13616280 | 0.81 | ALK (0.56) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL11976969 | 0.80 | CDK4 (0.68) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL12639344 | 0.80 | CDK4 (0.69) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL1355734 | 0.80 | CDK4 (0.69) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL7170319 | 0.80 | CDK4 (0.52) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL5868586 | 0.80 | CDK4 (0.58) | CDK4CCND1CCND3CCND2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | CDK4 4/4885CCND1 615/4885CCND3 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.